The manufacturing and trafficking of counterfeit drugs is not just a U.S. concern but a growing threat globally. Governments around the world are working together to try to prevent these fake products from reaching and harming patients. While the U.S. market is the most secure with a closed supply chain, there remains the threat of counterfeit and adulterated drugs reaching U.S. patients. This risk increases dramatically if medicines are imported from and travel through other countries before reaching the United States because there would be no way to ensure the safety and efficacy of those products.
In the past, we’ve highlighted one case study looking at the trajectory of developing counterfeit cancer drugs, how the drugs ended up in the United States and how the U.S. Food and Drug Administration rapidly worked to remove the counterfeit medicines from the U.S. market. That is just one example of a counterfeit drug that happened to reach the United States.
There are other examples of counterfeit drugs that have been found abroad that are a good indication of the kinds of counterfeits out there that are a risk to the United States. Take for example the discovery of counterfeit hepatitis C drugs in Israel.
- A counterfeiter in India began developing and selling a fake hepatitis C medicine.
- The counterfeiter then shipped the fake drugs through a Swiss trading company to Israel and Switzerland.
- It was only then that they were discovered and regulators began investigating where the drugs came from. Those regulators are still investigating, hoping to determine if the fake drugs ended up in any other countries.
Since that discovery, fake hepatitis C drugs have been found twice. Authorities in Pakistan raided a factory and discovered an illicit manufacturer in the process of making fake versions of the hepatitis C treatment, and counterfeit versions of the drug have been discovered in a legitimate pharmacy chain in Japan. It is not yet known if these counterfeits were from the same source.
New medicines for hepatitis C have the potential to cure more than 90 percent of treated patients, but not if counterfeit drugs are delivered to patients instead.
It is instances like this that illustrate the risks associated with importation of medicines. Foreign governments, including Canada, have stated they cannot guarantee the safety and efficacy of medicines sent from or through their countries to the United States. Opening U.S. borders to a flood of foreign products that may or may not be what they claim to be threatens the safety and security of our drug distribution system and unnecessarily places patients’ lives at risk.
Learn more about why drug importation is bad for patients here.
Nicole Longo
Nicole Longo is Deputy Vice President of public affairs at PhRMA focusing on Medicare, 340B, importation and more. She previously worked for a D.C.-based public affairs firm where she assisted a wide range of clients with communications efforts on everything from trade policy to agriculture policy to health care policy. Outside the office, Nicole can be found trying new restaurants (usually Italian), taking an occasional barre class and cheering on the Cincinnati Bengals.
Nicole Longo
More oversight needed of unapproved medicines that threaten patients’ health
What they are saying: Florida Drug Importation Program is Unfeasible and Dangerous
Florida’s importation plan puts patients in danger
Study finds hepatitis C cure saved Medicaid $15 billion
Three things to know about the accelerated approval pathway
ICYMI: Antimicrobial resistance spotlighted as growing public health threat
Why drug importation is bad for Americans
Recognizing Hepatitis R&D on World Hepatitis Day
PhRMA submits comments on FDA’s proposed rule on drug importation
Drug importation: An old idea that is still a bad idea
What they’re saying: Safety is top concern for recent drug importation proposal
ICYMI: Canadian government, stakeholders voice concerns with drug importation proposals
PhRMA responds to Florida’s request for information on drug importation
PhRMA CEO raises concerns with Florida importation proposal, highlights reforms needed to lower costs for patients
Look at the facts. Drug importation is dangerous.
Why state drug importation pilot programs don’t work
ICYMI: Wall Street Journal highlights dangers of counterfeit medicines entering the United States through drug importation
Securely dispose of your unwanted medicines on National Take Back Day
Spending on medicines grew less than one percent in 2017
The Washington Post retracts PhRMA claim in opioid story
PhRMA response to Washington Post and 60 Minutes stories
VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria
Protect your health: Important disaster preparedness tips for Harvey and Irma
PhRMA Supports President’s Commission’s Holistic Approach on Opioid Crisis
Opportunities to build upon enhanced competition for medicines in the marketplace
A critical opportunity to prevent prescription drug abuse
Former law enforcement officials raise concerns with drug importation proposals
The risks of counterfeit imported medicines
Medicare Monday: Another example of the competitive market at work in Part D
Resources for understanding the dangers of drug importation
ICYMI: What the experts are saying about importation
How drug importation schemes could increase U.S. law enforcement burdens
Case Study: How one online pharmacy knowingly endangered U.S. consumers
Why drug importation threatens patient safety
Fact Check Friday: The truth about drug importation and patient safety
What you don’t know about importation from Canada
Discovery of counterfeit hepatitis C drug is another example of why importation is bad for patients
Counterfeit Drugs
Prescription Drug Safety
Hepatitis C
Importation
Discovery of counterfeit hepatitis C drug is another example of why importation is bad for patients
Discovery of counterfeit hepatitis C drug is another example of why importation is bad for patients